Multiple sclerosis and COVID-19: How could therapeutic scenarios change during the pandemic?
作者信息
Mantero Vittorio, Abate Lucia, Salmaggi Andrea, Cordano Christian
机构信息
Department of Neurology, MS Center, ASST Lecco, Lecco, Italy.
Department of Neurology, MS Center, ASST Lariana, Como, Italy.
出版信息
J Med Virol. 2021 Apr;93(4):1847-1849. doi: 10.1002/jmv.26796. Epub 2021 Jan 22.
Abstract
摘要
相似文献
1
Multiple sclerosis and COVID-19: How could therapeutic scenarios change during the pandemic?
J Med Virol. 2021 Apr;93(4):1847-1849. doi: 10.1002/jmv.26796. Epub 2021 Jan 22.
2
Multiple sclerosis and COVID-19.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Sep;164(3):217-225. doi: 10.5507/bp.2020.033. Epub 2020 Jul 17.
3
Treatment of multiple sclerosis under the COVID-19 pandemic.
Tidsskr Nor Laegeforen. 2020 Apr 29;140(8). doi: 10.4045/tidsskr.20.0333. Print 2020 May 26.
4
Management of Patients with Multiple Sclerosis During the COVID-19 Pandemics: A Portuguese Single-Centre Experience.
Acta Med Port. 2021 Feb 1;34(2):162. doi: 10.20344/amp.15187. Epub 2021 Jan 6.
5
Keeping standards of multiple sclerosis care through the COVID-19 pandemic.
Mult Scler. 2020 Sep;26(10):1153-1156. doi: 10.1177/1352458520931785. Epub 2020 Jun 19.
6
The COVID-19 pandemic and the use of MS disease-modifying therapies.
Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.
7
Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic.
Neurol Sci. 2020 May;41(5):1007-1009. doi: 10.1007/s10072-020-04391-9. Epub 2020 Apr 17.
8
Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era.
Mult Scler Relat Disord. 2021 Apr;49:102715. doi: 10.1016/j.msard.2020.102715. Epub 2020 Dec 24.
9
Multiple sclerosis following SARS-CoV-2 infection.
Mult Scler Relat Disord. 2020 Oct;45:102377. doi: 10.1016/j.msard.2020.102377. Epub 2020 Jul 7.
10
COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile.
Mult Scler Relat Disord. 2020 Jul;42:102204. doi: 10.1016/j.msard.2020.102204. Epub 2020 May 16.
引用本文的文献
1
SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal.
Mult Scler Relat Disord. 2022 Jul;63:103893. doi: 10.1016/j.msard.2022.103893. Epub 2022 May 16.
2
Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination.
Vaccines (Basel). 2022 Feb 11;10(2):279. doi: 10.3390/vaccines10020279.
本文引用的文献
1
Impact of disease-modifying drugs on the severity of COVID-19 infection in multiple sclerosis patients.
J Med Virol. 2021 Mar;93(3):1314-1319. doi: 10.1002/jmv.26593. Epub 2020 Oct 30.
2
Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.
J Neurol. 2021 Jun;268(6):2029-2030. doi: 10.1007/s00415-020-10196-9. Epub 2020 Aug 31.
3
Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients.
Mult Scler Relat Disord. 2020 Nov;46:102453. doi: 10.1016/j.msard.2020.102453. Epub 2020 Aug 19.
4
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
Mult Scler Relat Disord. 2020 Oct;45:102452. doi: 10.1016/j.msard.2020.102452. Epub 2020 Aug 16.
5
Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach.
Ther Clin Risk Manag. 2020 Jul 22;16:651-662. doi: 10.2147/TCRM.S257714. eCollection 2020.
6
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Mult Scler. 2020 Sep;26(10):1264-1266. doi: 10.1177/1352458520943783. Epub 2020 Aug 7.
7
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.
Mult Scler Relat Disord. 2020 Oct;45:102402. doi: 10.1016/j.msard.2020.102402. Epub 2020 Jul 17.
8
Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab.
Mult Scler Relat Disord. 2020 Sep;44:102314. doi: 10.1016/j.msard.2020.102314. Epub 2020 Jun 20.
9
COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis.
J Neurol. 2021 Jun;268(6):2023-2025. doi: 10.1007/s00415-020-10015-1. Epub 2020 Jun 25.
10
COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series.
Mult Scler Relat Disord. 2020 Jul;42:102192. doi: 10.1016/j.msard.2020.102192. Epub 2020 May 16.
Zotero 插件